UNLIMITED TURBO SHORT - ELI LILLY & CO | Market Closed - Bid/Ask 01:06:51 25/06/2024 am IST | Pre-market 12:12:31 pm | |||
| 19.64 EUR | -4.52% |
|
19.84 | +1.04% |
| Current month | -25.69% | ||
| 1 month | -27.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 19.64 | -4.52% |
| 21/24/21 | 20.57 | -0.77% |
| 20/24/20 | 20.73 | +6.36% |
| 19/24/19 | 19.49 | -2.31% |
| 18/24/18 | 19.95 | -1.82% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 01:06 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68P2 |
| ISIN | DE000PC68P27 |
| Date issued | 25/03/2024 |
| Strike | 1,102 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 30.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 35.67 € |
|---|---|
| Lowest since issue | 18.97 € |
| Spread | 0.15 € |
| Spread % | 0.75% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
890.1
USD
Average target price
860.5
USD
Spread / Average Target
-3.32%
- Stock Market
- Certificates
- Certificat
